Table.

Areas Under the Curve (AUCs) for Clinical and Pharmacokinetic Measures (Mean ± SD)

MEASURE	Levodopa Infusions on Day 1 Following 4 weeks of Carbidopa1		Levodopa Infusions on Day 2 Concomitant Carbidopa		P2
	75 mg/day	450 mg/day	75 mg	450 mg
Tapping (taps/min) 0900–1400	141 ± 103	145 ± 123	141 ± 131	201 ± 214	0.336
Walking (seconds) 0900–1400	27 ± 66	30 ± 90	36 ± 90	37 ± 114	0.526
Tremor (score)0900–1400	2.6 ± 5.9	1.2 ± 2.2	1.1 ± 1.2	1.4 ± 3.4	0.789
Dyskinesia (score) 0900–1400	27 ± 28	23 ± 23	23 ± 19	23 ± 23	0.733
Levodopa (µg/ml) 0900–1400	5.38 ± 1.38	5.91 ± 1.64	5.23 ± 1.23	6.13 ± 1.453	0.014
Carbidopa (µg/ml) 0800–1400	0.55 ± 0.29	0.75 ± 0.413	0.47 ± 0.23	3.58 ± 1.564	0.001

¹Carbidopa 25 mg was administered at 8 AM, 10 AM and 12 PM during the infusions

²One way ANOVA with repeated measures

³Different from infusions following carbidopa 75 mg/day in outpatient phase

⁴Different from all infusions using 75 mg carbidopa